Substance use care innovations during COVID-19: barriers and facilitators to the provision of safer supply at a toronto COVID-19 isolation and recovery site.
COVID-19
Isolation site
Opioid use disorder
Overdose
Safe supply
Safer supply
Shelter
Substance use
Journal
Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624
Informations de publication
Date de publication:
20 Jan 2024
20 Jan 2024
Historique:
received:
23
05
2023
accepted:
09
01
2024
medline:
20
1
2024
pubmed:
20
1
2024
entrez:
19
1
2024
Statut:
epublish
Résumé
Early in the COVID-19 pandemic, there was an urgent need to establish isolation spaces for people experiencing homelessness who were exposed to or had COVID-19. In response, community agencies and the City of Toronto opened COVID-19 isolation and recovery sites (CIRS) in March 2020. We sought to examine the provision of comprehensive substance use services offered to clients on-site to facilitate isolation, particularly the uptake of safer supply prescribing (prescription of pharmaceutical opioids and/or stimulants) as part of a spectrum of comprehensive harm reduction and addiction treatment interventions. We conducted in-depth, semi-structured interviews with 25 clients and 25 staff (including peer, harm reduction, nursing and medical team members) from the CIRS in April-July 2021. Iterative and thematic analytic methods were used to identify key themes that emerged in the interview discussions. At the time of implementation of the CIRS, the provision of a safer supply of opioids and stimulants was a novel and somewhat controversial practice. Prescribed safer supply was integrated to address the high risk of overdose among clients needing to isolate due to COVID-19. The impact of responding to on-site overdoses and presence of harm reduction and peer teams helped clinical staff overcome hesitation to prescribing safer supply. Site-specific clinical guidance and substance use specialist consults were crucial tools in building capacity to provide safer supply. Staff members had varied perspectives on what constitutes 'evidence-based' practice in a rapidly changing, crisis situation. The urgency involved in intervening during a crisis enabled the adoption of prescribed safer supply, meeting the needs of people who use substances and assisting them to complete isolation periods, while also expanding what constitutes acceptable goals in the care of people who use drugs to include harm reduction approaches.
Sections du résumé
BACKGROUND
BACKGROUND
Early in the COVID-19 pandemic, there was an urgent need to establish isolation spaces for people experiencing homelessness who were exposed to or had COVID-19. In response, community agencies and the City of Toronto opened COVID-19 isolation and recovery sites (CIRS) in March 2020. We sought to examine the provision of comprehensive substance use services offered to clients on-site to facilitate isolation, particularly the uptake of safer supply prescribing (prescription of pharmaceutical opioids and/or stimulants) as part of a spectrum of comprehensive harm reduction and addiction treatment interventions.
METHODS
METHODS
We conducted in-depth, semi-structured interviews with 25 clients and 25 staff (including peer, harm reduction, nursing and medical team members) from the CIRS in April-July 2021. Iterative and thematic analytic methods were used to identify key themes that emerged in the interview discussions.
RESULTS
RESULTS
At the time of implementation of the CIRS, the provision of a safer supply of opioids and stimulants was a novel and somewhat controversial practice. Prescribed safer supply was integrated to address the high risk of overdose among clients needing to isolate due to COVID-19. The impact of responding to on-site overdoses and presence of harm reduction and peer teams helped clinical staff overcome hesitation to prescribing safer supply. Site-specific clinical guidance and substance use specialist consults were crucial tools in building capacity to provide safer supply. Staff members had varied perspectives on what constitutes 'evidence-based' practice in a rapidly changing, crisis situation.
CONCLUSION
CONCLUSIONS
The urgency involved in intervening during a crisis enabled the adoption of prescribed safer supply, meeting the needs of people who use substances and assisting them to complete isolation periods, while also expanding what constitutes acceptable goals in the care of people who use drugs to include harm reduction approaches.
Identifiants
pubmed: 38243267
doi: 10.1186/s12954-024-00935-w
pii: 10.1186/s12954-024-00935-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
17Informations de copyright
© 2024. The Author(s).
Références
Government of Canada. Health Infobase. 2022 [cited 2022 Oct 6]. Opioid- and Stimulant-related Harms in Canada. Available from: https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/
Russell C, Ali F, Nafeh F, Rehm J, LeBlanc S, Elton-Marshall T. Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): a national qualitative study. J Subst Abuse Treat. 2021;129:108374.
doi: 10.1016/j.jsat.2021.108374
pubmed: 34080545
pmcid: 9757985
Tyndall M. Safer opioid distribution in response to the COVID-19 pandemic. Int J Drug Policy. 2020;83:102880.
doi: 10.1016/j.drugpo.2020.102880
pubmed: 32739148
pmcid: 7383133
Gomes T, Murray R, Kolla G, Leece P, Bansal S, Besharah J, et al. Changing Circumstances Surrounding Opioid-Related Deaths in Ontario during the COVID-19 Pandemic [Internet]. ODPRN. 2021 [cited 2023 Jan 24]. Available from: https://odprn.ca/research/publications/opioid-related-deaths-in-ontario-during-covid/
Kolla G, Long C, Rucchetto A, Worku F, Fagundes R, Hayman K, et al. Evaluation of the Substance Use Services at a COVID-19 Isolation and Recovery Site in Toronto: A MARCO Report [Internet]. Toronto, ON: MAP Centre for Urban Health Solutions, St. Micahel’s Hospital, Unity Health; 2021 Dec. Available from: https://maphealth.ca/wp-content/uploads/SUS_MARCO-JAN-2022.pdf
Fleming MD, Evans JL, Graham-Squire D, Cawley C, Kanzaria HK, Kushel MB, et al. Association of shelter-in-place hotels with health services use among people experiencing homelessness during the COVID-19 pandemic. JAMA Netw Open. 2022;5(7):e2223891.
doi: 10.1001/jamanetworkopen.2022.23891
pubmed: 35895061
pmcid: 9331083
Fuchs JD, Carter HC, Evans J, Graham-Squire D, Imbert E, Bloome J, et al. Assessment of a hotel-based COVID-19 isolation and quarantine strategy for persons experiencing homelessness. JAMA Netw Open. 2021;4(3):e210490.
doi: 10.1001/jamanetworkopen.2021.0490
pubmed: 33651111
pmcid: 7926291
Brothers TD, Leaman M, Bonn M, Lewer D, Atkinson J, Fraser J, et al. Evaluation of an emergency safe supply drugs and managed alcohol program in COVID-19 isolation hotel shelters for people experiencing homelessness. Drug Alcohol Depend. 2022;1(235):109440.
doi: 10.1016/j.drugalcdep.2022.109440
Lew B, Bodkin C, Lennox R, O’Shea T, Wiwcharuk G, Turner S. The impact of an integrated safer use space and safer supply program on non-fatal overdose among emergency shelter residents during a COVID-19 outbreak: a case study. Harm Reduct J. 2022;19(1):29.
doi: 10.1186/s12954-022-00614-8
pubmed: 35313903
pmcid: 8935259
Canadian Association of People who Use Drugs. Safe Supply Concept Document. 2019 Feb;16. Available from: https://www.capud.ca/capud-resources/safe-supply-projects
Young S, Kolla G, McCormack D, Campbell T, Leece P, Strike C, et al. Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada. Int J Drug Policy. 2022;1(102):103601.
doi: 10.1016/j.drugpo.2022.103601
Glegg S, McCrae K, Kolla G, Touesnard N, Turnbull J, Brothers TD, et al. “COVID just kind of opened a can of whoop-ass”: the rapid growth of safer supply prescribing during the pandemic documented through an environmental scan of addiction and harm reduction services in Canada. Int J Drug Policy. 2022;106:103742.
doi: 10.1016/j.drugpo.2022.103742
pubmed: 35679695
pmcid: 9170132
Young S, Gomes T, Kolla G, McCormack D, Dodd Z, Raboud J, et al. Initiations of safer supply hydromorphone increased during the COVID-19 pandemic in Ontario: an interrupted time series analysis. PLoS ONE. 2023;18(12):e0295145.
doi: 10.1371/journal.pone.0295145
pubmed: 38113220
pmcid: 10729949
Gomes T, Kolla G, McCormack D, Sereda A, Kitchen S, Antoniou T. Clinical outcomes and health care costs among people entering a safer opioid supply program in Ontario. CMAJ. 2022;194(36):E1233–42.
doi: 10.1503/cmaj.220892
pubmed: 36122919
pmcid: 9484622
Ivsins A, Boyd J, Mayer S, Collins A, Sutherland C, Kerr T, et al. “It’s helped me a lot, just like to stay alive”: a qualitative analysis of outcomes of a novel hydromorphone tablet distribution program in vancouver. Can J Urban Health. 2021;98(1):59–69.
doi: 10.1007/s11524-020-00489-9
pubmed: 33118145
Kolla G, Long C, Perri M, Bowra A, Penn R. Safer Opioid Supply Program: Preliminary Report [Internet]. London: London Intercommunity Health Center; 2021 Nov p. 44. Available from: https://lihc.on.ca/wp-content/uploads/2022/01/2021-SOS-Evaluation-Full.pdf
McMurchy D, Palmer RW. Assessment of the Implementation of Safer Supply Pilot Projects [Internet]. Ottawa, Ontario; 2022 Mar p. 88. Available from: https://www.canada.ca/en/health-canada/services/opioids/responding-canada-opioid-crisis/safer-supply/early-findings-safer-supply-pilot-projects.html
Haines M, O’Byrne P. Safer opioid supply: qualitative program evaluation. Harm Reduct J. 2023;20(1):53.
doi: 10.1186/s12954-023-00776-z
pubmed: 37081500
pmcid: 10117245
Bardwell G, Ivsins A, Mansoor M, Nolan S, Kerr T. Safer opioid supply via a biometric dispensing machine: a qualitative study of barriers, facilitators and associated outcomes. CMAJ. 2023;195(19):E668–76.
doi: 10.1503/cmaj.221550
pubmed: 37188370
pmcid: 10185363
Gagnon M, Rudzinski K, Guta A, Schmidt RA, Kryszajtys DT, Kolla G, et al. Impact of safer supply programs on injection practices: client and provider experiences in Ontario, Canada. Harm Reduct J. 2023;20(1):81.
doi: 10.1186/s12954-023-00817-7
pubmed: 37380995
pmcid: 10303300
Schmidt RA, Kaminski N, Kryszajtys DT, Rudzinski K, Perri M, Guta A, et al. ‘I don’t chase drugs as much anymore, and I’m not dead’: Client reported outcomes associated with safer opioid supply programs in Ontario, Canada. Drug Alcohol Rev. 2023;42(7):1825–37. https://doi.org/10.1111/dar.13745 .
doi: 10.1111/dar.13745
pubmed: 37718646
Nafeh F, Mbichila T, Bouck Z, Scheim A, Mitra S, Bonn M, et al. A preliminary assessment of short-term social and substance use-related outcomes among clients of integrated safer opioid supply pilot programs in Toronto. Canada Int J Ment Health Addict. 2023. https://doi.org/10.1007/s11469-023-01219-3 .
doi: 10.1007/s11469-023-01219-3
Perri M, Fajber K, Guta A, Strike C, Kolla G. Outcomes from the Safer Supply Program in Kitchener-Waterloo. Report 1. 2023 Aug. Available from: https://www.nss-aps.ca/sites/default/files/resources/2023-KWSaferSupplyReport1.pdf
Karamouzian M, Rafat B, Kolla G, Urbanoski K, Atkinson K, Bardwell G, et al. Challenges of implementing safer supply programs in Canada during the COVID-19 pandemic: a qualitative analysis. International Journal of Drug Policy. 2023;1(120):104157.
doi: 10.1016/j.drugpo.2023.104157
Kalicum JV. “We need all the help we can get”: A Qualitative Examination of Service Provider Perspectives on the Barriers and Facilitators to the Implementation of The Emergency Risk Mitigation Guidelines [Internet]. University of Victoria; 2023. Available from: https://dspace.library.uvic.ca/bitstream/handle/1828/15052/Kalicum_Jeremy_MPH_2023.pdf?sequence=1&isAllowed=y
Macevicius C, Gudiño Pérez D, Norton A, Kolla G, Beck-McGreevy P, Selfridge M, et al. Just have this come from their prescription pad: the medicalization of safer supply from the perspectives of health planners in BC, Canada. Drugs Edu Prev Policy. 2023;1(1):1–11.
Foreman-Mackey A, Pauly B, Ivsins A, Urbanoski K, Mansoor M, Bardwell G. Moving towards a continuum of safer supply options for people who use drugs: a qualitative study exploring national perspectives on safer supply among professional stakeholders in Canada. Subst Abuse Treat Prev Policy. 2022;17(1):66.
doi: 10.1186/s13011-022-00494-y
pubmed: 36209227
pmcid: 9547673
Willows M, Brasch J, Sobey P, Tanguay R, Martell D. Is all “Safe Supply” Safe? Can J Addict. 2020;11(1):30–1.
doi: 10.1097/CXA.0000000000000079
BC Centre on Substance Use. Risk Mitigation In the Context of Dual Public Health Emergencies (V1.5) [Internet]. 2020. Available from: https://www.bccsu.ca/wp-content/uploads/2022/02/Risk-Mitigation-Guidance-Update-February-2022.pdf
Institut Universitaire sur les Dépendences & Québec. Substance Replacement Therapy in the Context of the COVID-19 Pandemic in Québec: Clinical Guidance for Prescribers [Internet]. 2020 [cited 2023 Apr 2]. Available from: https://dependanceitinerance.ca/wp-content/uploads/2020/10/Guide-Pharmaco-COVID_ANG-VF.19.10.20.pdf
Lie AK, Hansen H, Herzberg D, Mold A, Jauffret-Roustide M, Dussauge I, et al. The harms of constructing addiction as a chronic, relapsing brain disease. Am J Public Health. 2022;112(S2):S104–8.
doi: 10.2105/AJPH.2021.306645
pubmed: 35349310
pmcid: 8965190
Frank D. “I Was Not Sick and I Didn’t Need to Recover”: methadone maintenance treatment (MMT) as a refuge from criminalization. Subst Use Misuse. 2018;53(2):311–22.
doi: 10.1080/10826084.2017.1310247
pubmed: 28704148
Kleinman RA, Wakeman SE. Treating opioid withdrawal in the hospital: a role for short-acting opioids. Ann Intern Med. 2022;175(2):283–4.
doi: 10.7326/M21-3968
pubmed: 34807718
Thakrar AP. Short-acting opioids for hospitalized patients with opioid use disorder. JAMA Intern Med. 2022;182(3):247–8.
doi: 10.1001/jamainternmed.2021.8111
pubmed: 35099508
Thakrar AP, Uritsky TJ, Christopher C, Winston A, Ronning K, Sigueza AL, et al. Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder. Addict Sci Clin Pract. 2023;18(1):13.
doi: 10.1186/s13722-023-00368-z
pubmed: 36829242
pmcid: 9951406
Bonn M, Touesnard N, Cheng B, Pugliese M, Comeau E, Bodkin C, et al. Securing safe supply during COVID-19 and beyong: Scoping review and knowledge mobilization [Internet]. 2020 p. 76. Available from: https://cihr-irsc.gc.ca/e/52043.html
Hales, Kolla G, Man T, O’Reilly E, Rai N, Serada A. Safer Opioid Supply Programs (SOS): A harm reduction informed guiding document for primary care teams - April 2020 update [Internet]. 2019 [cited 2023 Jan 24]. Available from: https://docs.google.com/document/d/e/2PACX-1vTMQEhchBfmTjeBxpDRi6w7pXE5EDuInMiKARuxBcxvFUtjPmqk8l7AFPGYvWn3hOHWkTMo8-m5QPI0/pub
Ministry of Mental Health and Addictions, Ministry of Health. Access to Prescribed Safer Supply in British Columbia: Policy Direction. July 15, 2021. Available from: https://www2.gov.bc.ca/assets/gov/overdose-awareness/prescribed_safer_supply_in_bc.pdf
The College of Physicians and Surgeons. Advice to the Profession: Prescribing Drugs [Internet]. 2020 [cited 2023 Jan 24]. Available from: https://www.cpso.on.ca/Physicians/Policies-Guidance/Policies/Prescribing-Drugs/Advice-to-the-Profession-Prescribing-Drugs
Hadju P. Letter from the Minister of Health regarding treatment and safer supply [Internet]. 2020. Available from: https://www.canada.ca/en/health-canada/services/substance-use/minister-letter-treatment-safer-supply.html
Haines M, Tefoglou A, O’Byrne P. Safer Supply Ottawa Evaluation [Internet]. Ottawa; 2022 p. 55. Available from: https://safersupplyottawa.com/wp-content/uploads/SS-Ottawa-Evaluation-Report-Fall-2022.pdf